Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
With
Array BioPharma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic breast cancer (Part 2).
Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy (patients with HER2+ breast cancer and with clinical indication for trastuzumab or lapatinib should have received prior therapy with trastuzumab and lapatinib, if available).
Eastern Cooperative Oncology Group (ECOG) performance status (PS) between 0 and 2.
Additional criteria exist.
You may not be if
Uncontrolled or symptomatic brain metastases (patients may be considered adequately controlled if on a stable steroid dose for at least 30 days).
Treatment with an investigational medicinal product or device within 30 days prior to first dose of study drug.
Radiotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites).
Chemotherapy within 21 days prior to first dose of study drug.
Major surgery within 30 days prior to first dose of study drug.
Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.
Additional criteria exist.
Clareo Health | A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
